PT - JOURNAL ARTICLE ED - , TI - Management of corticosteroid-induced osteoporosis AID - 10.1136/dtb.2010.09.0047 DP - 2010 Sep 01 TA - Drug and Therapeutics Bulletin PG - 98--101 VI - 48 IP - 9 4099 - http://dtb.bmj.com/content/48/9/98.short 4100 - http://dtb.bmj.com/content/48/9/98.full SO - Drug Ther Bull2010 Sep 01; 48 AB - Relevant BNF section: BNF 6.6 Treatment with corticosteroids can adversely affect bone metabolism. In particular, it lowers bone mineral density (BMD) and increases the likelihood of fragility fractures, the hallmarks of osteoporosis, hence the term ‘corticosteroid-induced osteoporosis’.1 Since corticosteroids are used for a wide variety of inflammatory conditions, corticosteroid-induced osteoporosis represents a substantial disease burden. Here we aim to provide advice on prophylaxis and treatment for osteoporosis in adults receiving corticosteroid therapy.